Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2002

View Archived Issues

Elan sells remaining stock in Athena Diagnostics

Better antihyperlipidemic profile reported for metformin plus pioglitazone in type 2 diabetes

Potential use of pirfenidone in progressive renal disease

Renoprotective effects of ALT-711 in diabetic rats

A novel prostate cancer vaccine reported to induce specific immune responses

New data on the immunomodulatory effects of IL-2 + histamine in advanced melanoma

Preclinical and preliminary clinical data reported for Pyridorin

Galapagos Genomics awarded grant for bone disease research

Morphochem enters research collaboration with AstraZeneca for novel antithrombotics

Miravant discusses phase III SnET2 data with FDA

Canadian approval for Thymoglobulin in renal transplant patients

Expanded indication for EmdogainGel in E.U.

Acambis completes phase I trial of dengue vaccine component

Rotigotine CDS reduces symptoms of restless legs syndrome in phase II trial

PDE4 and/or PDE7 inhibitors identified at Altana Pharma

New folate analogues for the delivery of therapeutic and diagnostic agents

Vertex presents novel inhibitors of caspase and TNF-alpha production

Allergan licenses rights to PEP-005 from Peplin Biotech

New series of HDAC inhibitors prepared and tested by Roche researchers

Novel alpha2delta ligands with utility in neuropathic pain and other disorders

Pharmacia claims new alpha7 nicotinic acetylcholine receptor agonists

Chemokine CXCR3 antagonists designed by Millennium and Kyowa Hakko

Phase I IND cleared for LY-674

SRP-299 enters phase II in childhood atopic dermatitis

Cotara receives orphan drug status in E.U.

European Commission grants marketing authorization for Zavesca

CD22-targeted immunoconjugate characterized at EORTC-NCI-AACR meeting

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...